Emerging within the UK, retatrutide, a innovative molecule, is sparking considerable excitement within the healthcare community regarding its ability for physique control . This dual GIP and GLP-1 target agonist looks to provide a considerable advantage over current therapies, showing encouraging results in initial clinical assessments. Researchers